loading...| Preferred Name |
Bicalutamide |
|
| Synonyms |
4'-Cyano-alpha,alpha,alpha-trifuloro-3-[(p-fluorophenyl)sulfonyl]-2-methyl-m-lactotoluidide ICI 176,334 (+/-)-N-[4-Cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide BICALUTAMIDE N-[4-Cyano-3-(trifluoromethyl)phenyl]3-3[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-propanamide bicalutamide 4-Cyano-3-trifluoromethyl-N-(3-p-fluorophenylsulfonyl-2-hydroxy-2-methylpropionyl)aniline Bicalutamide Casodex Cosudex ICI 176334 |
|
| Definitions |
A synthetic, nonsteroidal antiandrogen. Bicalutamide competitively binds to cytosolic androgen receptors in target tissues, thereby inhibiting the receptor binding of androgens. This agent does not bind to most mutated forms of androgen receptors. (NCI04) |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1599 |
|
| Accepted_Therapeutic_Use_For |
Metastatic prostate cancer |
|
| ALT_DEFINITION |
An anticancer drug that belongs to the family of drugs called antiandrogens. |
|
| CAS_Registry |
90357-06-5 |
|
| CHEBI_ID |
CHEBI:3090 |
|
| Chemical_Formula |
C18H14F4N2O4S |
|
| code |
C1599 |
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C192234 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173381 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C173383 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C201600 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784 |
|
| Contributing_Source |
CTRP FDA GDC HemOnc OORO |
|
| DEFINITION |
A synthetic, nonsteroidal antiandrogen. Bicalutamide competitively binds to cytosolic androgen receptors in target tissues, thereby inhibiting the receptor binding of androgens. This agent does not bind to most mutated forms of androgen receptors. (NCI04) |
|
| Display_Name |
Bicalutamide |
|
| FDA_UNII_Code |
A0Z3NAU9DP |
|
| FULL_SYN |
4'-Cyano-alpha,alpha,alpha-trifuloro-3-[(p-fluorophenyl)sulfonyl]-2-methyl-m-lactotoluidide ICI 176,334 (+/-)-N-[4-Cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide BICALUTAMIDE N-[4-Cyano-3-(trifluoromethyl)phenyl]3-3[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-propanamide bicalutamide 4-Cyano-3-trifluoromethyl-N-(3-p-fluorophenylsulfonyl-2-hydroxy-2-methylpropionyl)aniline Bicalutamide Casodex Cosudex ICI 176334 |
|
| Has_Target | ||
| Is_Value_For_GDC_Property | ||
| label |
Bicalutamide |
|
| Legacy Concept Name |
Bicalutamide |
|
| Maps_To |
Bicalutamide |
|
| NCI_Drug_Dictionary_ID |
41298 |
|
| NSC Number |
722665 |
|
| PDQ_Closed_Trial_Search_ID |
41298 |
|
| PDQ_Open_Trial_Search_ID |
41298 |
|
| Preferred_Name |
Bicalutamide |
|
| prefixIRI |
Thesaurus:C1599 |
|
| Semantic_Type |
Organic Chemical Pharmacologic Substance |
|
| UMLS_CUI |
C0285590 |
|
| subClassOf |